Clinical Trials Logo
  1. Home
  2. ADPKD
  3. NCT00345137

Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis

Glomerulonephritis Clinical Trial

Official title:
Phase 1 Study of Systemic Effects of Ng-Monomethyl-L-Arginine on Renal Hemodynamics in Patients With Polycystic Kidney Disease and Chronic Glomerulonephritis

Clinical Trial Summary

The study tests the hypothesis that systemic and renal nitric oxide availability is changed in polycystic kidney disease and chronic glomerulonephritis.

Clinical Trial Description

In a randomized, placebo controlled design, the effects of systemic treatment with monomethyl-L-arginine are studied on:

1. renal hemodynamics

2. renal sodium excretion and lithium clearance

3. blood pressure and heart rate

4. plasma levels of vasoactive hormones

in patients with adult polycystic kidney disease and chronic glomerulonephrits. The results are compared with a group of healthy control subjects ;

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00345137
Study type Interventional
Source Regional Hospital Holstebro
Contact
Status Completed
Phase Phase 1
View Details
See also
  Status Clinical Trial Phase
Completed NCT00001457 - Lamivudine for Chronic Hepatitis B Phase 2
Recruiting NCT05505955 - Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency Phase 1
Recruiting NCT01240564 - The Nephrotic Syndrome Study Network (NEPTUNE) N/A
Active, not recruiting NCT05174221 - A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy Phase 1
Completed NCT00426348 - A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Phase 4
Recruiting NCT04662723 - Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Phase 4
Completed NCT02700516 - Recurrent Glomerulonephritis After Renal Transplantation N/A
Recruiting NCT00862693 - Calcitriol in the Treatment of Immunoglobulin A Nephropathy Phase 4
Completed NCT00983034 - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy N/A
Completed NCT00004990 - Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis Phase 2
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Terminated NCT04387448 - A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Phase 2
Terminated NCT04950114 - An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases Phase 2
Completed NCT00437463 - Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor Phase 3
Terminated NCT02523768 - Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Phase 4
Completed NCT00106561 - Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney Phase 2/Phase 3
Completed NCT04733040 - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) Phase 2
Completed NCT00001676 - Cyclophosphamide and Fludarabine to Treat Lupus Nephritis Phase 1
Recruiting NCT02063100 - Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis Phase 4
Completed NCT01093157 - A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy Phase 1/Phase 2